In fusion gene negative AML patients, possible targets for PCR-based MRD assessment are Fms-like tyrosine kinase- internal tandem duplication (FLT3-ITD), mutated nucleophosmin1 (NPM1),and DNA methyltransferase(DNMT3A). The gene discussed is NPM1; the disease is acute myeloid leukemia.